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Introduction {#sec001}
============

Obesity is an increasing concern among people living with HIV (PWH). Several studies have reported an increasing prevalence of being overweight and obese in PWH, and have demonstrated that weight gain occurs in many PWH after initiating antiretroviral therapy (ART) \[[@pone.0229617.ref001]--[@pone.0229617.ref004]\]. Factors associated with weight gain in PWH include demographic factors (such as sex and race), HIV disease-related factors (such as disease stage and viral load), and ART-associated factors (specific antiretroviral drugs) \[[@pone.0229617.ref002], [@pone.0229617.ref003], [@pone.0229617.ref005]--[@pone.0229617.ref009]\]. These observations have led to several non-exclusive mechanistic hypotheses for ART-associated weight gain, including a mirroring of societal trends, a return-to-health effect of ART, improved tolerability of ART regimens, and off-target effects of antiretroviral drugs.

Among the antiretroviral drugs, the integrase strand transfer inhibitors (INSTIs) have specifically been associated with weight gain in studies of treatment-naïve PWH and in PWH switching to INSTI-based therapy \[[@pone.0229617.ref002], [@pone.0229617.ref007], [@pone.0229617.ref008], [@pone.0229617.ref010]\]. Whether this association is causative is unknown, and no mechanism to explain the association has been demonstrated. Clinical data on the effect of INSTIs on appetite has not been reported to date. An off-target effect of INSTIs has been hypothesized as a potential mechanism, based on data discussed in the European Products Assessment Report for the INSTI dolutegravir (DTG), which states that DTG can inhibit the binding of endogenous ligand to the human MC4R *in vitro* \[[@pone.0229617.ref011]\].

The regulation of body weight is a complex, integrated process linking peripheral signals of energy stores to homeostatic responses. Key centers in the brain provide overarching control of processes that regulate food intake (via satiation and appetite, and hedonic mechanisms) and energy metabolism \[[@pone.0229617.ref012]\]. The prevailing overview of the central control of food intake highlights the role of the hypothalamic melanocortin system, whereby peptides derived from the precursor protein proopiomelanocortin (POMC) inhibit feeding behavior via their agonistic action on central melanocortin-3 and -4 receptors (MC3R, MC4R) \[[@pone.0229617.ref013]\]. Conversely, blockade of MC4R by the agouti-related protein (AgRP) increases feeding \[[@pone.0229617.ref014]\], and complete loss of MC3R or MC4R in mice is associated with increased food intake and concomitant obesity \[[@pone.0229617.ref015], [@pone.0229617.ref016]\]. Mutations in MC4R that render the receptor less- or non-responsive to POMC-derived peptides are commonly associated with human obesity \[[@pone.0229617.ref017]\]. Thus, the notion that modulation of the melanocortin system can influence food intake and body weight homeostasis is supported by rodent and clinical evidence from both genetic and pharmacological paradigms.

In this study, we have investigated the potential for approved INSTIs to interfere with endogenous ligand binding to MC4R thereby potentially providing a plausible explanation for the clinical body weight gain noted. Specifically, cellular functional assays were performed to delineate potential antagonistic or agonist effects of the following INSTIs: bictegravir (BIC), dolutegravir (DTG), cabotegravir (CAB), raltegravir (RAL), and elvitegravir (EVG). Comparisons of antagonism or agonism in the cellular assays (IC~50~ values) to clinical C~max~ at the recommended dosages are provided.

Materials and methods {#sec002}
=====================

Materials {#sec003}
---------

Biochemical binding assays were conducted at Eurofins Cerep France and functional cellular assays were conducted at Eurofins Panlabs Discovery Services Taiwan, Ltd. Both studies were sponsored by Gilead Sciences Inc. All assay reagents and materials, including agonist reference compounds α-melanocyte stimulating hormone (α-MSH) and melanotan II and antagonist reference compounds AgRP and HS024 were obtained by the testing sites (Eurofins). Test compounds (BIC, DTG, CAB, RAL, EVG) were supplied by Gilead Sciences Inc.

Biochemical binding assay {#sec004}
-------------------------

Binding assays were conducted to evaluate the affinity of test compounds for the human MC4R in transfected CHO cells by radioligand binding (Eurofins Cerep Catalog Item 420). Cell membrane homogenates (about 23 μg protein) were incubated for 120 min at 37°C with 0.05 nM \[125I\]NDP-α-MSH in the absence or presence of the test compound in a buffer containing 25 mM Hepes/KOH (pH 7.0), 100 mM NaCl, 1.5 mM CaCl2, 1 mM MgSO4, 0.2 g/l 1.10 phenanthroline and 0.1% BSA. Nonspecific binding was determined in the presence of 1 μM NDP-α-MSH. Following incubation, the samples were filtered rapidly under vacuum through glass fiber filters (GF/B, Packard) presoaked with 0.3% PEI and rinsed several times with ice-cold 50 mM Tris-HCl using a 96-sample cell harvester (Unifilter, Packard). The filters were dried then counted for radioactivity in a scintillation counter (Topcount, Packard) using a scintillation cocktail (Microscint 0, Packard). The results are expressed as a percent inhibition of the control radioligand specific binding: 100-((measured specific binding)/(control specific binding)×100).

The standard reference compound is NDP-α-MSH, which is tested in each experiment at several concentrations to obtain a competition curve from which its IC~50~ was calculated. Test compounds were initially screened at 100 μM and run at 8 concentrations based on screening results to determine the IC~50~.

Functional cellular assays {#sec005}
--------------------------

Functional assays were conducted to evaluate the activity of test compounds for the MC4R in transfected CHO cells by measuring cAMP release using a time-resolved fluorescence resonance energy transfer (TR-FRET) method (Eurofins Panlabs Item 332270). Commercially available frozen, irradiated CHO-K1 cells with transfected human recombinant melanocortin MC4 receptor were used (PerkinElmer Part ES-191-AF). Test compound and/or vehicle was incubated with the cells (2.5 x 10E5/ml) in modified HBSS pH 7.4 buffer at 37°C for 20 minutes. The reaction was evaluated for cAMP levels by TR-FRET using a commercially available kit (PerkinElmer LANCE™ cAMP 384 kit). Test compound-induced cAMP increase by 50 percent or more (≥50%) relative to the 3 μM NDP a MSH control response indicated possible receptor agonist activity. Test compound-induced inhibition of the 10 nM NDP-a-MSH induced cAMP response by 50 percent or more (≥50%) indicated possible receptor antagonist activity. Test compounds, including concurrent known agonist and antagonist controls, were run at 6 concentrations selected based on biochemical binding assay results to determine the IC~50~.

Calculation of IC~50~ values {#sec006}
----------------------------

The IC~50~ values (concentration causing a half-maximal inhibition of control specific binding) and Hill coefficients (nH) were determined by non-linear regression analysis of the competition curves generated with mean replicate values using Hill equation curve fitting $Y = D + \left\lbrack \frac{A - D}{1 + \left( {C/C_{50}} \right)^{nH}} \right\rbrack$ where Y = specific binding, A = left asymptote of the curve, D = right asymptote of the curve, C = compound concentration, C50 = IC~50~, and nH = slope factor.

For biochemical binding assays, analysis was performed using software developed at Cerep (Hill software) and validated by comparison with data generated by the commercial software SigmaPlot® 4.0 for Windows® (© 1997 by SPSS Inc.). For functional cellular assays, analysis was performed using MathIQ™ (ID Business Solutions Ltd., UK).

Results {#sec007}
=======

The objective of an initial screening study was to evaluate the potential for various INSTIs to interfere with ligand binding to the MC4R in an *in vitro* biochemical assay. Specifically, binding was calculated as % inhibition of the binding of a radioactively labeled ligand (NDP-α-MSH), specific for MC4R, at a fixed concentration of each INSTI (100 μM). Any result showing an inhibition greater than 50% was considered to represent a significant effect and followed-on by determination of IC~50~ values using a multi-dose concentration curve. The initial biochemical binding assay at a single 100 μM concentration showed a range from 55% to 91% binding inhibition for the five INSTIs evaluated ([S1 Table](#pone.0229617.s002){ref-type="supplementary-material"}). Specifically, in this study DTG showed 91% inhibition at 100 μM compared to the previously reported inhibition binding value of 64% at 10 μM \[[@pone.0229617.ref011]\]. Given the significant binding for all compounds assayed (\>50%), IC~50~ values were determined, and ranged from 0.46 μM to 78 μM.

To further evaluate the biochemical findings in a more physiologically relevant system, we performed cell-based *in vitro* MC4R antagonism and agonism assays. Validity and specificity of the assays were established with the concurrent inclusion of MC4R agonist or antagonist positive controls ([Table 1](#pone.0229617.t001){ref-type="table"}). Positive controls for antagonism included AgRP or HS024 or SHU9119, with potent effects at relatively low concentrations in alignment with historical data (per vendor confirmation). Positive controls for agonism included the endogenous agonist αMSH, MTII, and NDP-α-MSH which likewise showed selective results. Overall, concurrent positive controls for antagonism or agonism confirmed the assays performed as anticipated.

10.1371/journal.pone.0229617.t001

###### Summary of MC4R agonism and antagonism assay results and clinical C~max~ margins for INSTIs.

![](pone.0229617.t001){#pone.0229617.t001g}

  Compound    Agonist                                      Antagonist                                                  
  ----------- -------------------------------------------- ------------ ---------------------------------------------- --------
  BIC         \>100                                        \>2900       \>100                                          \>2900
  DTG         \>100                                        \>1600       69.4                                           1120
  CAB         \>30                                         \>1200       \>30                                           \>1200
  EVG         \>300                                        \>13000      2.75                                           120
  RAL         \>300                                        \>160        \>300                                          \>160
  AgRP        \-                                           \-           0.012                                          NA
  HS024       \-                                           \-           0.23                                           NA
  SHU9119     \-                                           \-           0.0069[^b^](#t001fn003){ref-type="table-fn"}   NA
  α-MSH       0.49                                         NA           \-                                             \-
  MT II       0.0054                                       NA           \-                                             \-
  NDP-α-MSH   1.67[^b^](#t001fn003){ref-type="table-fn"}   NA           \-                                             \-

'NA'--data not available.

a Estimated margin based upon clinical C~max~ (unbound) for BIC (0.034 μM), DTG (0.062 μM), CAB (0.025 μM), EVG (0.0225 μM), or RAL (1.9 μM) based upon clinical dose.

b Mean based upon on multiple independent determinations.

INSTIs evaluated in the functional cellular *in vitro* assay for potential antagonistic or agonistic effects are listed in [Table 1](#pone.0229617.t001){ref-type="table"}. Exposure margins comparing the *in vitro* assay to the human clinical exposures were determined by dividing the IC~50~ values by the clinical C~max~ (unbound; protein-free) values based upon maximum approved clinical dose ([S2 Table](#pone.0229617.s003){ref-type="supplementary-material"}). It is noted that for BIC, DTG, and CAB, the highest concentration of INSTI evaluated was limited by compound solubility in the cellular buffer solution. However, overall, no agonistic effects were observed at any concentration of INSTIs evaluated; IC~50~ values were not able to be determined up to the highest concentrations tested. As a result, exposure margins for MC4R agonism based upon IC~50~ values were greater than 160- to 13,000-fold versus the clinical C~max~ (unbound) values. For the antagonism assay, IC~50~ values were calculated for DTG (69.4 μM) or EVG (2.75 μM) resulting in C~max~ margins of 1120- or 120-fold, respectively. The remaining INSTIs evaluated, BIC, CAB, and RAL, were tested up to maximum dose concentrations of 100, 30, or 300 μM (based upon solubility for BIC or CAB), respectively, and IC~50~ values were unable to be determined, resulting in C~max~ margins of greater than 2900-, 1200-, or 160-fold, respectively. [Fig 1](#pone.0229617.g001){ref-type="fig"} further depicts the considerable margin between IC~50~ calculations and C~max~ from the clinical dose for antagonistic effects.

![Depiction of MC4R antagonism assay results and clinical C~max~ margins for INSTIs.\
Lines depict the substantial difference between the clinical dose C~max~ value (protein-free) and the reported EC~50~ value in the MC4R antagonism assay for each INSTI evaluated.](pone.0229617.g001){#pone.0229617.g001}

Discussion {#sec008}
==========

Due to the potential off-target liability of MC4R for body weight gain cited for DTG, and observed body weight gain in patients receiving INSTIs, a number of INSTIs were evaluated for potential interaction with MC4R in cellular functional antagonist or agonist assays. Overall, our data demonstrate that all tested INSTIs have the ability to antagonize the MC4R receptor to some degree, but importantly, inhibition occurs only at drug concentrations substantially greater than the therapeutic plasma concentrations of each drug, ranging from 160-fold to \>13,000-fold greater than unbound C~max~. Furthermore, the relative IC~50~ values for the INSTIs tested are inconsistent with their relative risk for clinical weight gain. For instance, DTG is associated with greater weight gain than EVG \[[@pone.0229617.ref018]\], however EVG was approximately 25-fold more potent in MC4R antagonism than DTG in our experiments. These findings suggest that it is unlikely that MC4R antagonism contributes to the weight gain associated with INSTI use.

There are several limitations to our findings. Our data are derived from an *in vitro* assay, and thus do not recreate the physiological milieu in which a potential interaction between INSTIs and MC4R would occur *in vivo*. For instance, because MC4R is localized primarily to the hypothalamus, the ratio of MC4R IC~50~ to plasma free drug concentrations may not be physiologically relevant. However, studies using cerebrospinal fluid INSTI concentration as a surrogate for central nervous system penetration have documented CSF drug levels equal to or less than free plasma levels, making it unlikely that more free drug is available for interaction with MC4R in the central nervous system \[[@pone.0229617.ref019]--[@pone.0229617.ref021]\]. It is noted that following daily oral administration with BIC in repeat dose toxicity studies, no effects on body weight gain in mice (4 weeks), rats (26 weeks), or cynomolgous monkeys (39 weeks) were reported with AUC plasma exposure levels at 16- to 30-fold the BIC plasma exposure at the clinical dose of 50 mg in Biktarvy^®^. While we do not know what fractional antagonism of MC4R is needed to induce weight gain, the dose-response relationships we have observed make it unlikely that the INSTI concentrations achieved in clinical practice would induce physiologically relevant antagonism of MC4R.

The regulation of body weight can also be modified via manipulation of other signaling pathways independent of MC4R. In nonclinical models, activation of the melanin-concentrating hormone receptor-1 \[[@pone.0229617.ref022]\], neuropeptide-Y receptors \[[@pone.0229617.ref023], [@pone.0229617.ref024]\] or ghrelin receptor \[[@pone.0229617.ref025]\] leads to weight gain. Whether INSTIs are able to activate these receptors is unknown. Furthermore, other MC4R-independent pathways are pharmacologically utilized to promote weight loss. One example is the glucagon-like peptide-1 (GLP-1) pathway, wherein synthetic peptide agonists of the GLP-1 receptor drive weight loss and are currently approved for the treatment of diabetes and obesity \[[@pone.0229617.ref026]\]. In nonclinical models, blockade or loss of GLP-1 receptors does not promote weight gain \[[@pone.0229617.ref027]\], however it remains a possibility that INSTIs may affect the GLP-1 receptor or its ligands in a clinical setting to the extent it may increase body weight. These hypotheses remain to be directly tested. In summary, our findings demonstrate a class-wide ability of INSTIs to bind and antagonize MC4R only at very high drug concentrations, making the INSTI-MC4R interaction implausible as a molecular mechanism to explain INSTI-associated weight gain. Further work is needed to understand potential explanations for the observed association between INSTI use and weight gain.

Supporting information {#sec009}
======================

###### Example of antagonism response curve for INSTI EVG.

EC~50~ value in the MC4R antagonism assay illustrated for EVG and positive control (SHU9119).

(TIF)

###### 

Click here for additional data file.

###### Biochemical binding assay.

(DOCX)
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Click here for additional data file.

###### Human C~max~ values for approved INSTIs at recommended clinical dosages.

(DOCX)

###### 

Click here for additional data file.
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weight gain.
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Reviewer \#2: McMahon and colleagues examined the impact of several integrase strand transfer inhibitors (INSTIs) on melanocortin-4 receptor (MC4R) activity. Given the recent increase in prevalence of excess weight gain in patients with HIV, particularly after initiating treatment with INSTIs, several hypotheses have been suggested to explain this weight gain including a potential interaction of INSTIs with the MC4R, leading to its inhibition promoting hyperphagia and reduced energy expenditure. Using in vitro assays in CHO cells transfected with human MC4R, the authors showed that although every INSTI compound exhibit significant binding to the MC4R and evoked inhibition of MC4R-induced activation of cAMP, the doses required for significant inhibition were far too greater than anticipated clinical circulating levels of free INSTI. Thus, the authors concluded that potential inhibition of MC4R by INSTIs is likely not the main mechanism behind the excess weight gain observed in INSTI-treated HIV patients.
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Reviewer \#1:

We thank the reviewer for this comment. Weight loss if, of course, extremely complicated and regulated by many central and peripheral pathways in homeostatic coordination. The first reference refers to evidence that liraglutide, a GLP-1 receptor agonist, can exert weight loss when infused directly to the brain and was associated with increased MC4R expression, thereby implicating that the weight loss may in part be due to melanocortin activity. The second paper refers to weight loss effects of liraglutide being equivalent in obese patients with or without MC4R inactivating mutations. The point is well taken, that additional mechanisms may be in play beyond MC4R. This is certainly true, and an additional paragraph has therefore been added to the discussion, where we discuss potential effects of agonism or antagonism of several pathways known to modulate food intake/body weight, at least in rodents. Very few pathways have been successfully targeted for weight loss therapy in a clinical setting. However, we list several of them as areas of potential future research on INSTI-associated weight gain.
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The authors appreciate the reviewer comments. The request for the potential evaluation of MC4R KO animals while treated with INSTIs was discussed among authors, however was considered outside of the scope of this body of work. The authors did add to the text the description of the lack of effect on body weight in repeat dose toxicology studies with bictegravir in rat, mouse or cynomolgous monkeys for dosing periods up to 39 weeks when administered daily.
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The authors appreciate the suggested additions and/or revisions. The revised version with track changes reflect the list of recommendation. However, due to publicly available chemical structures for all INSTIs evaluated, the authors did not feel inclusion of the chemical structures was warranted in this case. Also, due to the sheer volume of graphs illustrating the biochemical binding of INSTIs evaluated with associated positive controls, the authors have chosen to include a representative figure for EVG only, which was associated with the lowest corresponding Cmax margin.

Reviewer \#4:

Thank you for your forward-looking comment recommending the inclusion of future research to be conducted. Please see response above to Reviewer \#1.

10.1371/journal.pone.0229617.r003

Decision Letter 1

Spradley

Frank T.

Academic Editor

© 2020 Frank T. Spradley

2020

Frank T. Spradley

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

11 Feb 2020

Lack of an association between clinical INSTI-related body weight gain and direct interference with MC4 receptor (MC4R), a key central regulator of body weight

PONE-D-19-27424R1

Dear Dr. McMahon,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Frank T. Spradley

Academic Editor

PLOS ONE

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#2: All comments have been addressed

Reviewer \#3: All comments have been addressed

Reviewer \#4: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#2: No additional comments except that inclusion of in vivo studies in MC4R KO model would strengthen the manuscript.

Reviewer \#3: (No Response)

Reviewer \#4: (No Response)

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#2: Yes: Alexandre A. da Silva

Reviewer \#3: Yes: Serguei Fetissov

Reviewer \#4: Yes: Oya Ercan

10.1371/journal.pone.0229617.r004

Acceptance letter

Spradley

Frank T.

Academic Editor

© 2020 Frank T. Spradley

2020

Frank T. Spradley

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

12 Feb 2020

PONE-D-19-27424R1

Lack of an association between clinical INSTI-related body weight gain and direct interference with MC4 receptor (MC4R), a key central regulator of body weight

Dear Dr. McMahon:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Frank T. Spradley

Academic Editor

PLOS ONE

[^1]: **Competing Interests:**The funder (Gilead Sciences) provided support in the form of salaries for all authors, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
